Cholesterol
pill boosts cancer immunotherapy, at least in mice
Send a link to a friend
[March 17, 2016]
LONDON (Reuters) - Tweaking
cholesterol levels with a simple pill may boost the effectiveness of new
immunotherapy drugs that are starting to revolutionize the treatment of
cancers, experiments in mice suggest.
|
Two new drugs from Bristol-Myers Squibb and Merck, Opdivo and
Keytruda, help the body's immune system fight tumors and are already
being used to fight lung cancer, kidney cancer and melanoma.
But such so-called checkpoint inhibitors, which are also being
developed by Roche, AstraZeneca and Pfizer, do not work for all
patients, prompting scientists to search for improvements.
One option could be to modify cholesterol levels, since this can
increase the anti-cancer activity of immune cells known as killer T
cells, Chenqi Xu of the Chinese Academy of Sciences and colleagues
reported in the journal Nature on Thursday.
In particular, they found that adding the drug avasimibe to
checkpoint drugs that block a protein called Programmed Death
receptor (PD-1) improved tumor inhibition and increased survival in
mice.
"These data show that avasimibe and anti-PD-1 act through different
pathways and have additive effects in cancer immunotherapy," they
wrote.
Avasimibe was originally developed by Pfizer, which at one stage saw
it as a potential contender to succeed its blockbuster cholesterol
fighter Lipitor. But it was dropped from development after failing
to treat cardiovascular disease as well as hoped.
[to top of second column] |
Nonetheless, it can still be used in clinical trials and it has the
advantage of being administered as a pill.
Michael Dustin of the University of Oxford, who wrote an
accompanying comment about the latest research, said it was
"exciting to speculate" that doctors might one day be able to
prescribe a pill to boost cancer immunotherapy.
(Reporting by Ben Hirschler; Editing by Greg Mahlich)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|